Modeling Clinical Outcomes in Gambling Addiction
MOGADOR
2 other identifiers
observational
268
1 country
9
Brief Summary
Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences. MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients. For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months). MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Longer than P75 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 5, 2025
CompletedFirst Posted
Study publicly available on registry
May 20, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2030
May 20, 2025
May 1, 2025
4 years
May 5, 2025
May 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Partial remission of gambling disorder at 12 months (strictly less than 4 DSM-5 criteria)
Assessment of DSM-5 criteria will be performed by the clinician, and by a previously trained CRA if clinical follow-up is discontinued.
DSM-5 criteria assessment will be conducted at 9 and 12 months after inclusion.
modeling prognostic factors
The prognostic factors, studied will be: number of initial DSM-5 criteria, gender, age, marital status, housing, employment status, socioeconomic level, time spent gambling, impulsivity, type of gambling, location of gambling, and also the factor with the strongest association in univariate analysis among the following factors: * Depression (PHQ scale), * Anxiety (GAD scale), * Quality of life (SF-36 scale).
at inclusion visit.
Study Arms (1)
Patients with gambling disorder
OGADOR will focus exclusively on patients with DSM-5 criteria for gambling disorder and on demand for medical care. In this study psychiatric and addictological comorbidities, frequent in such a cohort, will constitute a specific inclusion factor, key characteristic leading an analysis of the impact on the patient prognosis.
Eligibility Criteria
268 patients with gambling disorder according to DSM-5 criteria newly managed in one of the participating centers or who had an interruption in management of more than 6 months.
You may qualify if:
- Patient, male or female, over 18 years old, consulting in one of the participating centers.
- First treatment for gambling disorder or no treatment in the last 6 months (initiation or re-initiation of care).
You may not qualify if:
- Unable to be reached by phone.
- Unable to use the internet.
- Patient under antiparkinsonian treatment of the dopaminergic family.
- Being treated with a drug that may trigger/increase symptoms of gambling disorder (e.g. dopamine agonist).
- Subject under guardianship.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Hôpital Jen Minjoz, CHU de Besançon
Besançon, 25030, France
Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier
Bron, 69500, France
Service Universitaire d'Addictologie de Lyon (SUAL), Groupement Hospitalier Est
Bron, 69500, France
Service Universitaire d'Addictologie, CHU de Clermont-Ferrand
Clermont-Ferrand, 63000, France
Name of location * Service d'Addictologie, Groupe Hospitalier Seclin Carvin
Lille, 59000, France
Centre Expert Régional du Jeu Pathologique (CERJeP Limousin)
Limoges, 87000, France
Service Universitaire d'Addictologie, CHU de Nîmes
Nîmes, 30000, France
Assistance Publique des Hôpitaux de Paris, Hôpital Marmottan
Paris, 75017, France
Hôpital de Bellevue, CHU de St-Etienne
Saint-Etienne, 42000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 5, 2025
First Posted
May 20, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
September 1, 2029
Study Completion (Estimated)
September 1, 2030
Last Updated
May 20, 2025
Record last verified: 2025-05